Sermorelin
GHRH analog studied for endogenous GH signaling.
Evidence Level
Moderate
Research Type
/ System Mapping
Where this compound appears in research pathways
Research-only note: This mapping is educational and does not represent a treatment protocol.
/ 01
Overview
GHRH analog studied for endogenous GH signaling.
/ 02
Mechanism of Action
Studied for GHRH receptor activation and physiologic GH pulses.
/ 03
Research Applications
GH/IGF-1 axis research.
Studied for, research explores, preclinical models suggest, clinical studies have investigated.
/ 04
Studied Research Contexts
/ 05
Studied Research Dosing Ranges
Limited public data on dosing ranges across research models.
/ 06
Potential Adverse Effects Reported in Research
Adverse effect data is limited. Many compounds in this database lack human safety profiles.
/ 07
Mechanism Deep Dive
Sermorelin is a synthetic analog of the first 29 amino acids of GHRH. Research describes stimulation of endogenous growth hormone release from the anterior pituitary, with downstream effects on the GH/IGF-1 axis.
/ 08
Pathway Role
Sits within the hypothalamic-pituitary GH axis at the GHRH receptor signaling layer.
/ 09
Biological Targets
/ 10
Research Applications
- Pediatric GH stimulation testing (historical)
- Adult GH axis research
- Endocrine response studies
/ 11
Evidence Summary
Older endocrine literature documents acute hormonal response. Long-term outcome data for general use is limited.
Evidence Level Rationale
Rated moderate within hormonal-response research; limited outside that endocrine context.
/ 12
Research Observation Timeline
Early Signal Window
Acute GH response within minutes to hours in controlled studies
Primary Study Window
Days to weeks for hormonal endpoints
Endpoint Type
Hormonal biomarker endpoints
Evidence Strength
Moderate for acute endocrine response
/ 13
Safety & Unknowns
Acute use in research has documented tolerability. Long-term outcome and safety in general populations is not established.
/ 14
Research Limitations
Most data is acute hormonal response. Long-term body composition or outcome timing is not established.
/ 15
References
References are being curated from peer-reviewed literature.
/ 07
Evidence Score
Overall Research Confidence
Moderate
Reflects breadth of mechanism, study type, and reproducibility across research literature.
/ 08
Related Peptides
Semaglutide
GLP-1 receptor agonist studied for glycemic and weight research.
Tirzepatide
Dual GIP/GLP-1 agonist studied in metabolic research.
Retatrutide
Triple agonist (GLP-1, GIP, glucagon) studied in metabolic trials.
Appears in pathways
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.